Literature DB >> 9856795

Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment.

N A Syed1, J J Windle, S R Darjatmoko, J M Lokken, R A Steeves, R Chappell, I H Wallow, B A Koop, G Mangold, K A Howes, D M Albert.   

Abstract

PURPOSE: To describe the cell of origin, tumor progression, light and electron microscopic appearance, immunohistochemical properties, and response to frequently used anticancer therapies in two transgenic models of intraocular melanoma.
METHODS: Two lines of transgenic mice that develop pigmented intraocular tumors were produced with the SV40 T and t antigens under the control of the mouse tyrosinase gene. Tumors were sequentially studied and characterized by light microscopy, electron microscopy, and immunohistochemistry stains. Tumor response to two cycles of dacarbazine was assessed on the basis of tumor size in one group of animals. Response to external beam irradiation was measured by survival time in other animals.
RESULTS: Two lines of transgenic mice developed bilateral intraocular tumors with complete penetrance and without primary cutaneous melanomas. Tumors developed first in the retinal pigment epithelial layer, with subsequent retinal and choroidal invasion, extraocular extension, and metastasis. Tumors stained positive for S-100, HMB-45, and Fas-ligand. Electron microscopy revealed polarization of tumor cells with basement membrane formation, microvilli, immature melanosomes, and abundant endoplasmic reticulum. Dacarbazine significantly reduced tumor size in these mice, and a trend toward dose-dependent decrease in survival was found with external beam irradiation.
CONCLUSIONS: Tumors developed from the retinal pigment epithelium. Their histology and growth, however, closely resembled that of human choroidal melanoma. This model may be a useful tool for future studies of endogenous primary pigmented tumors limited to the eye. Response to standard therapies suggests it can serve as a model with which to evaluate therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856795

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

Review 1.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility.

Authors:  Shoujian Wang; Aneesh Neekhra; Daniel M Albert; Christine M Sorenson; Nader Sheibani
Journal:  Arch Ophthalmol       Date:  2012-03

3.  Id2 deficiency promotes metastasis in a mouse model of ocular cancer.

Authors:  Olga A Agapova; Erica Person; J William Harbour
Journal:  Clin Exp Metastasis       Date:  2010-02-02       Impact factor: 5.150

4.  Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas.

Authors:  Michael D Onken; Justis P Ehlers; Lori A Worley; Jun Makita; Yoshifumi Yokota; J William Harbour
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 5.  Matricellular protein thrombospondins: influence on ocular angiogenesis, wound healing and immuneregulation.

Authors:  Sharmila Masli; Nader Sheibani; Claus Cursiefen; James Zieske
Journal:  Curr Eye Res       Date:  2014-02-21       Impact factor: 2.424

Review 6.  Authenticating cell lines in ophthalmic research laboratories.

Authors:  Robert Folberg; Shrihari S Kadkol; Shahar Frenkel; Klara Valyi-Nagy; Martine J Jager; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

7.  Modeling the behavior of uveal melanoma in the liver.

Authors:  Robert Folberg; Lu Leach; Klara Valyi-Nagy; Amy Y Lin; Marsha A Apushkin; Zhuming Ai; Vivian Barak; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

8.  ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.

Authors:  G De la Houssaye; V Vieira; C Masson; F Beermann; J L Dufier; M Menasche; M Abitbol
Journal:  Mol Vis       Date:  2008-10-29       Impact factor: 2.367

Review 9.  Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations.

Authors:  Marta M Stei; Karin U Loeffler; Frank G Holz; Martina C Herwig
Journal:  Biomed Res Int       Date:  2016-06-06       Impact factor: 3.411

Review 10.  Mouse models of uveal melanoma: Strengths, weaknesses, and future directions.

Authors:  Jackson R Richards; Jae Hyuk Yoo; Donghan Shin; Shannon J Odelberg
Journal:  Pigment Cell Melanoma Res       Date:  2020-01-22       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.